Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Acadia Pharmaceuticals revenue
Acadia Pharmaceuticals's revenue is $957.8 million.
What is Acadia Pharmaceuticals's revenue?
- Acadia Pharmaceuticals has 570 employees, and the revenue per employee ratio is $1,680,345.
- Acadia Pharmaceuticals's peak quarterly revenue was $259.6M in 2024(q4).
- Acadia Pharmaceuticals peak revenue was $957.8M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Acadia Pharmaceuticals financial information
| CEO | Stephen R. Davis |
| Industry | Health Care Equipment & Services |
| Company Type | Public |
| Employees Number | 570 |
| Date Founded | 1993 |
| Headquarters | San Diego, California |
| Number of Locations | 2 |
| Revenue | $957.8M |
| Net Income | -$215,975,000 |
| Gross Proft | $876.0M (2024) |
| Tax Rate | 0.1% |
| Total Assets | $587,812,000 |
| Ticker | ACAD |
Acadia Pharmaceuticals jobs you might like
Acadia Pharmaceuticals financing
Acadia Pharmaceuticals received early financing of $6.0M on 1997-02-04.
| Series | Round size | Date |
|---|---|---|
| Series A | $6M | 02/1997 |
| Debt Financing | $7.5M | 02/1997 |
| Series B | $3M | 08/1997 |
| Series D | $10.7M | 08/1998 |
| Debt Financing | $22M | 06/2000 |
| Series F | $25M | 03/2003 |
| Post Ipo Equity | $10M | 02/2005 |
| Post Ipo Equity | $20M | 02/2006 |
| Post Ipo Equity | $15M | 01/2011 |
| Grant | $2.4M | 05/2011 |
| Post Ipo Equity | $86.4M | 01/2013 |
| Post Ipo Equity | $316.2M | 11/2018 |
| Post Ipo Equity | $287.5M | 09/2019 |
Acadia Pharmaceuticals investors
| Investors | Security type |
|---|---|
| BankInvest | Series A |
| DKA Capital | Series A |
| LD Pensions | Series A |
| Vaekstfonden | Debt Financing |
| BankInvest | Series B |
| DKA Capital | Series B |
| LD Pensions | Series B |
| DKA Capital | Series D |
| LD Pensions | Series D |
| Pacific Rim Ventures | Debt Financing |
| H&Q Healthcare Investors | Debt Financing |
| The Kaufmann Fund | Debt Financing |
| OrbiMed Advisors | Debt Financing |
| DKA Capital | Debt Financing |
| Federated Hermes | Series F |
| Hambrecht & Quist Capital Management | Series F |
| Forbion Capital Partners | Series F |
| Oxford Bioscience Partners | Series F |
| OrbiMed Advisors | Series F |
| ABN AMRO Bank | Series F |
| LD Pensions | Series F |
| Oxford Bioscience Partners | Post Ipo Equity |
| Nomura Holdings Inc. | Post Ipo Equity |
| Oxford Bioscience Partners | Post Ipo Equity |
| New Enterprise Associates (NEA) | Post Ipo Equity |
| Venrock | Post Ipo Equity |
| National Institute of Neurological Disorders and Stroke (NINDS) | Grant |
Acadia Pharmaceuticals competitors
Acadia Pharmaceuticals's top competitor, Merck, earned an annual revenue of $64.2B.
Acadia Pharmaceuticals's smallest competitor is Promega with revenue of $450.0M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 359 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Human Genome Sciences | $70,157 | $131.0M | 1,000 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 707 |
| Amgen | $93,349 | $33.4B | 22,000 | 590 |
| Vertex Pharmaceuticals | $95,952 | $11.0B | 3,400 | 287 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Merck | $90,328 | $64.2B | 74,000 | 1,306 |
| Zoetis | $87,092 | $9.3B | 11,300 | 231 |
| Forest Laboratories | $91,901 | $3.6B | 6,200 | - |
Acadia Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Acadia Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Acadia Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Acadia Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Acadia Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Acadia Pharmaceuticals. The data presented on this page does not represent the view of Acadia Pharmaceuticals and its employees or that of Zippia.
Acadia Pharmaceuticals may also be known as or be related to ACADIA PHARMACEUTICALS INC, ACADIA Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc., Acadia Pharmaceuticals, Acadia Pharmaceuticals Inc. and Receptor Technologies.